ArticlePhysics and imaging in radiation oncology2026
Quantitative lung tissue functional analysis for pulmonary adverse event risk assessment prior to thoracic radiotherapy.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Pulmonary adverse events are a limiting factor in thoracic radiotherapy and more common in patients with pulmonary comorbidities. Parametric response mapping (PRM) is an effective method of providing 3-dimensional underlying lung comorbidity data. We hypothesized that a commercial PRM software could identify patients at increased risk of pulmonary adverse events during radiotherapy. Materials and methods: Paired inspiratory/expiratory computed tomography (CT) scans obtained during simulation were processed using Lung Density Analysis (LDA) to classify lung tissue as Normal, Functional Low Density (FLD), Persistent Low Density (PLD), and Inspiration High Density (IHD). Patients were classified as elevated FLD, PLD, or IHD using predetermined thresholds. Multivariable models investigated associations between grade ≥ 2 pulmonary adverse events and (i) LDA measures, and (ii) clinical lung disease history. Model discrimination was assessed using area under the receiver operating characteristic curve (AUC). Results: Among 98 patients receiving definitive-intent thoracic radiotherapy, 22 experienced grade ≥ 2 pulmonary adverse events. Elevated IHD (Odds Ratio [OR] = 2.95; 95% Confidence Interval [CI]:1.12-7.97; Conclusion: Elevated IHD was a significant predictor of pulmonary adverse events, with PLD demonstrating a similar but nonsignificant trend. LDA measures demonstrated predictive performance comparable to clinical lung disease history, suggesting potential utility as a risk-screening tool pending validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.